anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the technical field of pharmaceutical biology. Flt3L is one of colony stimulating factor family members, and can be used for stimulating the proliferation and differentiation of CD34+hemopoietic stem cells. The invention aims to provide a nucleic acid vaccine adjuvant with the enhanced activity of cellular immunity and a construction method thereof. The nucleic acid vaccine adjuvant is a plasmid which is designed based on the Flt3L and is used for enhancing the cellular immune effect of a nucleic acid vaccine. In-vivo experiments prove that when simultaneously injected with the nucleic acid vaccine, the plasmid has the capacity of inducing a cellular immune reaction effectively, such as increasing of antigen-specific spleen IFN-gamma positive cells and enhancement of the target killing capacity of spleen CD8 positive cells. Therefore, the vaccine adjuvant of the invention can be added into the conventional nucleic acid vaccine preparation for mixing injection, so that the cellular immune reaction induced by the nucleic acid vaccine is promoted obviously, and the nucleic acid vaccine is used as a novel cellular immune adjuvant.
Atrial fibrillation is a common supraventricular tachyarrhythmia with uncoordinated atrial activation and ineffective atrial contraction. This leads to an increased risk of atrial thrombi, most commonly in the left atrial appendage, and increased risks of embolic strokes and/or peripheral thromboembolism. It is associated with significant morbidity and mortality. To meet the concerns of thrombi and stroke, anticoagulation has been the mainstay for prevention and treatment thereof. Historically, anticoagulation involved the use of aspirin or vitamin K antagonists, mainly warfarin. Since early 2010s, direct oral anticoagulants (DOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban have been introduced and approved for anticoagulation of atrial fibrillation. DOACs demonstrated a dramatic reduction in the rate of intracranial hemorrhage as compared to warfarin, and offer the advantages of absolution of monitoring therefore avoid the risk of hemorrhages in the context of narrow therapeutic window and under-treatment characteristic of warfarin, particularly in high-risk patients. One major concern and disadvantage for DOACs was lack of reversal agents, which have largely been ameliorated by the approval of Idarucizumab for dabigatran and Andexanet alfa for both apixaban and rivaroxaban, with Ciraparantag as a universal reversal agent for all DOACs undergoing Fast-Track Review from FDA. In this article, we will be providing a broad review of anticoagulation for atrial fibrillation with a focus on risk stratification schemes and anticoagulation agents (warfarin, aspirin, DOACs) including special clinical considerations.
Intense exercise leads to increased production of free radicals, resulting in an inflammatory response in athletes. For this reason, it was decided to investigate whether a single intensive exercise until exhaustion applied after a 2-week rest period would result in a violation of the pro-oxidant-antioxidant balance. Twenty-seven trained female basketball players (age: 16.55 ± 0.96 years, body mass: 66.40 ± 13.68 kg, height: 173.45 ± 5.14 cm) were enrolled to the study following the application of inclusion and exclusion criteria. Study was conducted at the end of the competitive training phase. Participants underwent incremental treadmill exercise, with blood samples collected before the test, immediately post-exercise, and after a 3-h restitution period. Total antioxidant capacity (TAC) levels increased significantly after exercise and remained unchanged after 3 h. Concentration of interleukin-10 (IL-10) and creatine kinase (CK) significantly increased after exercise and then decreased. Concentration of interleukin-2 (IL-2) was significantly reduced immediately and 3 h after exercise, while interleukin-13 (IL-13), interleukin-1α (IL-1α), and tryptophan (TRP) decreased 3 h after exercise. No significant changes were observed in other biochemical parameters. Obtained results show an increased antioxidant capacity which reduced oxidative stress and inflammation in response to intense exercise indicating that rested athletes have a high adaptation and elevated tolerance to effort.
Intraocular steroid agents have been shown to decrease inflammatory cytokines in diabetic macular edema (DME) patients and thus have roles in the treatment of these patients. However, I believe that anti-VEGF could effectively decrease intraocular inflammatory responses in these patients with much fewer side effects than intraocular steroid agents.

Since soluble CD14 (sCD14) is the known marker of inflammatory cells including microglia, increased or decreased retinal inflammation accompanied by DME could be monitored using sCD14 in patients with DME. Recently, I published an article regarding the strong association of increased sCD14 in the aqueous humor (AH) from DME patients, especially in increased inner retinal edema as well as increased hyper reflective foci (HF) in optical coherence tomography (OCT). This associated changes of sCD14 levels and HF in the retina suggested that the HF might represent the activated microglia in DME. I also showed that the intravitreal bevacizumab injection resulted in a reduction of sCD14 in the AH and HF in OCT. However, that study was retrospective and I could not have many patients' follow-up data after bevacizumab treatments and thus was not able to get conclusive results regarding decreased retinal inflammation after anti-VEGF. Therefore, I believe that a well-desinged prospective study is needed to clarify whether retinal inflammation is ameliorated after anti-VEGF treatment. Moreover, I believe that aflibercept is more appropriate and better drug than bevacizumab to investigate the changes in the cytokine levels along with the improvement of inflammatory milieu in DME due to the following reasons. First, recent DRCR.net Protocol-T reported the superior clinical outome of aflibercept compared to bevacizumab on DME. Second, aflibercept has significantly higher binding affinity to VEGF-A compared to ranibizumab or bevacizumab. Third, aflibercept also binds to VEGF-B and placental growth factor (PlGF), unlike ranibizumab or bevacizumab. PlGF-VEGFR1 pathway contributes to inflammation by triggering production of proinflammatory cytokines.

Thus, I would like to investigate the efficacy of aflibercept for reducing inflammation in DME. Therapeutic effects of aflibercept on reduction of DME in the context of amelioration of inflammation will be proved using sCD14 and HF as surrogate markers in this proposed study. Besides sCD14, tracking the cytokines including MCP-1, IL-6, and ICAM-1 in the AH in a well-controlled prospective setting of aflibercept treatments will enhance our understanding regarding the role of inflammation on DME, and the importance of aflibercept for decreasing ocular inflammation in DME patients.
The invention discloses a recombined fusion protein VIP-TAT and application of the recombined fusion protein VIP-TAT. The amino acid sequence of the recombined fusion protein VIP-TAT is shown in SEQIDNO:1, and the nucleotide sequence for coding the protein is shown in SEQIDNO:2. The recombined fusion protein VIP-TAT disclosed by the invention has biological activities that VIP does not have, and the biological activities include efficiently activating an intracellular/nucleus located VIP receptor and restraining multiplication of colon cancer cell HT29. The recombined fusion protein VIP-TAT can enter the brain by absorption of the respiratory tract and remarkably increases the SOD (Superoxide Dismutase) level of the organism and remarkably resists learning and memory damage due to induction of scopolamine. The activities enable the CIP-TAT to have the application prospect that the VIP does not have in prevention and treatment of colon cancer, resistance of brain oxidative damage, resistance of learning and memory damage and prevention and treatment of senile dementia. Moreover, the VIP-TAT can be inhaled through the respiratory tract for medication, so that the medication route of the VIP-TAT is improved, the application range of the VIP-TAT is widened, and the application value of the VIP-TAT in brain and lung is greatly increased.
The invention discloses a medicine for treating cervical erosion, which belongs to the technical field of an innovative medicine preparation in traditional Chinese medicines. According to the product, a traditional Chinese medicinal material fructus cnidii in China is taken as a raw material, effective part total coumarins are obtained by extraction through the processes of alcohol extraction, concentration, acid/alkali purification and the like, and a vaginal effervescent tablet is prepared by processing through adopting a modern preparation technology. Because the direct contact of the medicine and a part with pathological change is increased by a great number of foam generated by the disintegration of the medicine for treating the cervical erosion, the curative action of the medicine for treating the cervical erosion is better exerted. The medicine for treating the cervical erosion is suitable for serving as a medicine for preventing and treating vaginal diseases. Moreover, the medicine for treating the cervical erosion is quick to disintegrate, is rapid to act and has high bioavailability. Moreover, the medicine for treating the cervical erosion is convenient to preserve and carry. The medicine disclosed by the invention has the effects of eliminating dampness, diminishing inflammation, removing putrefaction and promoting tissue regeneration and is mainly used for patients with syndromes, such as leukorrheal diseases caused by the damp invasion of lower energizers with the symptoms of much leukorrheal quantity and yellowness or whiteness in color, or purulency and sagging distention in the waist and the abdomen, or dribbling, difficulty and pain in urination, or pruritus vulvae, bitterness in the mouth, dryness in the throat, redness in the tongue, yellowness or greasiness in the fur, slipperiness or tautness in the pulse and the cervical erosion.
Disclosed is a formulation treating scalding, reducing inflammation and relieving pain, said formulation comprising an external application formulation and an oral formulation. The external application formulation comprises a paste formulation and a patch formulation. The paste formulation comprises the following, by gram: 5-20 grams of aloe, 5-20 grams of fresh torreya shell, 10-30 grams of raw radix sanguisorbae, 5-10 grams of raw rhubarb, 1-3 grams of borneol, 10-30 grams of cactus, 5-10 grams of sesame powder, 10-30 grams of fresh lotus leaf, 5-10 grams of camellia oil, 5-10 grams of olive oil, 1-3 grams of oyster oil, 1-3 grams of badger oil, and 5-20 grams of rice-washing water, mashed and mixed into a paste. The patch formulation comprises the following: white tofu slices, egg white, salt water, and sliced cucumber. The oral formulation comprises the following, by gram: 10-30 grams of fresh lotus leaf, 10-20 grams of fructus jujubae, and 5-15 grams of herba houttuyniae. The formulation treating scalding, reducing inflammation and relieving pain cools and refreshes the affected area during the treatment, performs inflammation reduction, swelling reduction, pain relief and itching relief on the affected area, promotes cellular regeneration, prevents bacteria and fungi from breeding, and achieves an effect of treating the root causes.
This study is intended to conduct a multicenter, observable and controlled cohort study in multiple clinical centers including the First Affiliated Hospital of Xi'an Jiaotong University to solid-tumor patients who received immunotherapy for the first time. The baseline information before treatment was collected (mainly including three collection methods, namely, patients' self filling information, physician assisted filling information, and medical record system import information. The information collected was mainly in the following aspects: demographic characteristics, tumor and anti-tumor information, gene testing information, blood sample collection information, and questionnaire evaluation information) and follow-up information after treatment (The collection method and content are the same as the baseline information.) Collect the relevant factors that may affect the treatment efficacy and prognosis of patients, build a prospective disease cohort database based on patient reports, and then analyze the risk factors that affect the efficacy, prognosis and adverse events of immunotherapy and the impact of immunotherapy on health status. The outcome indicators are mainly disease free progression survival (PFS), The secondary indicators were the total survival period (OS), ojective response rate (ORR), immune-related adverse events (irAEs) and the scoring results of various questionnaires (PHQ-9, etc). It is expected to provide high-level evidence-based medical evidence for the selection of immunotherapy schemes for these patients, the precise prevention and health management of adverse events after immunotherapy, and the further improvement of survival prognosis of patients.
The weight loss achieved with topiramate occurs through several purported mechanisms including reductions in appetite, food cravings, and binge eating, and adverse alterations in taste for carbonated beverages. It is hypothesized that some of the individual-level effectiveness of this medication on weight loss response is secondary to patient-specific differences in these factors. In a 3.5-month pragmatic-based prospective cohort study (n=65), the investigators will develop a popPK model using sparse sampling by drawing a series of topiramate concentration measures over time in order to begin determining patient-specific factors that contribute to topiramate exposure variability. The investigators will also identity associations between topiramate exposure, changes in eating behaviors, and weight loss outcomes through PD models using regression techniques. It is hypothesized that patient-specific characteristics (i.e. age, body mass index (BMI), and sex) will explain some variability in topiramate exposure in youth, and that higher topiramate exposure will be associated with greater improvements in weight loss response and eating behaviors among youth prescribed this medicine for the treatment of pediatric severe obesity.
Implantable medical devices having an anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of proteintyrosine kinase inhibitors are disclosed. The anti-restenotic protein-tyrosine kinase inhibitor is 4+4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and pharmaceutically acceptable derivatives thereof (imatinib mesylate). The anti-restenotic medial devices include stents, catheters, micro-particles, probes and vascular grafts. The medical devices can be coated using any method known in the art including compounding the protein-tyrosine kinase inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-protein-tyrosine kinase inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one proteintyrosine kinase inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the antirestenotic implantable devices are also disclosed.
All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
The incidence of Lyme borreliosis has risen, accompanied by persistent symptoms. The innate immune system and related cytokines are crucial in the host response and symptom development. We characterized cytokine production capacity before and after antibiotic treatment in 1,060 Lyme borreliosis patients. We observed a negative correlation between antibody production and IL-10 responses, as well as increased IL-1Ra responses in patients with disseminated disease. Genome-wide mapping the cytokine production allowed us to identify 34 cytokine quantitative trait loci (cQTLs), with 31 novel ones. We pinpointed the causal variant at the TLR1-6-10 locus and validated the regulation of IL-1Ra responses at transcritpome level using an independent cohort. We found that cQTLs contribute to Lyme borreliosis susceptibility and are relevant to other immune-mediated diseases. Our findings improve the understanding of cytokine responses in Lyme borreliosis and provide a genetic map of immune function as an expanded resource.
Sham cTMS will be delivered at as a placebo control. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active cTMS. This will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
This grup nursing diagnoses and expected nursing outcomes (NOC) appropriate to the needs of the individual were selected in a face-to-face interview 1 week before the procedure. The baseline measurements of NOCs were made. On the trading day, the after measurement of NOCs was made. But nursing process was not applied to this group.
OBJECTIVE: The serine protease inhibitor SerpinB3 has been described as critical mediator of liver fibrosis and it has been recently proposed as an additional hepatokine involved in NASH development and insulin resistance. Protease Activated Receptor 2 has been identified as a novel regulator of hepatic metabolism. A targeted therapeutic strategy for NASH has been investigated, using 1-Piperidine Propionic Acid (1-PPA), since this compound has been recently proposed as both Protease Activated Receptor 2 and SerpinB3 inhibitor.
METHODS: The effect of SerpinB3 on inflammation and fibrosis genes was assessed in human macrophage and stellate cell lines. Transgenic mice, either overexpressing SerpinB3 or carrying Serpinb3 deletion and their relative wild type strains, were used in experimental NASH models. Subgroups of SerpinB3 transgenic mice and their controls were also injected with 1-PPA to assess the efficacy of this compound in NASH inhibition.
RESULTS: 1-PPA did not present significant cell and organ toxicity and was able to inhibit SerpinB3 and PAR2 in a dose-dependent manner. This effect was associated to a parallel reduction of the synthesis of the molecules induced by endogenous SerpinB3 or by its paracrine effects both in vitro and in vivo, leading to inhibition of lipid accumulation, inflammation and fibrosis in experimental NASH. At mechanistic level, the antiprotease activity of SerpinB3 was found essential for PAR2 activation, determining upregulation of the CCAAT Enhancer Binding Protein beta (C/EBP-β), another pivotal regulator of metabolism, inflammation and fibrosis, which in turn determined SerpinB3 synthesis.
CONCLUSIONS: 1-PPA treatment was able to inhibit the PAR2 - C/EBP-β - SerpinB3 axis and to protect from NASH development and progression, supporting the potential use of a similar approach for a targeted therapy of NASH.
BACKGROUND: Various smartphone applications (apps) for people with tinnitus are available and promise tinnitus relief. Yet, it is difficult for people suffering from tinnitus and healthcare professionals to estimate their quality, potential, or risks. The current study aims to generate an overview of available tinnitus apps in the German language and to offer orientation for research and healthcare providers.
METHOD: The most prominent stores were searched systematically (November 2020-April 2021; Google Play Store and Apple App Store). Apps specifically developed for tinnitus were evaluated by two independent raters using multiple approaches: a) a quality screening was performed using the German version of the Mobile App Rating Scale (MARS-G), b) intervention components were assessed using a newly developed list of categories, and c) implemented strategies for active tinnitus management were analyzed using behavior change techniques (BCTs).
RESULTS: The search yielded 1073 apps, of which 21 apps were analyzed. The apps' overall quality as assessed by MARS‑G was average (M = 3.37, SD = 039). A lot of apps offered sounds (n = 18) and information (n = 9) or assessed tinnitus characteristics (n = 13). Out of 93 BCTs, 24 were identified at least once. Only one app was evaluated in non-randomized trials.
CONCLUSION: Although a variety of apps are available, most of them focus on a few intervention components (e.g., sounds or information). Therefore, apps do not exploit their potential to impart important evidence-based content for tinnitus management. The app evaluation using multiple approaches points out potential for improvement.
Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy
Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.